ARCHIMED Acquires a Majority Stake in Arkstone, Forging a Powerful Partnership to Accelerate Global Healthcare Innovation And Dominate the Emerging AI-Driven Clinical Decision Support Market

Arkstone, an innovative biotechnology company democratizing infectious disease expertise and fighting antimicrobial resistance, has been acquired by global healthcare private equity firm ARCHIMED, which now holds a majority stake.

BOCA RATON, Fla., July 30, 2025 /PRNewswire/ -- Arkstone, a pioneer in machine learning (ML) and artificial intelligence (AI)-driven infectious disease clinical decision support and antimicrobial stewardship, has announced being acquired by ARCHIMED, a leading private equity firm specializing in the healthcare sector.

The transaction marks a pivotal moment in Arkstone's growth trajectory, positioning the company to expand its global footprint, deepen its R&D capabilities, and bring its precision-guided technology to more clinicians around the world. Backed by ARCHIMED's capital, extensive healthcare expertise, and international reach, Arkstone is poised to scale its impact on the global fight against antimicrobial resistance (AMR), one of the most urgent public health threats of our time.

"Arkstone's OneChoice Report is redefining infectious disease management. Our partnership will enable Arkstone to reach more markets, accelerate product innovation, and ultimately save lives by reducing the misuse of antibiotics," said Igor Petricca, Partner at ARCHIMED. "This deal offers an additional dimension, as Clinical Decision Support software (CDS) and infectious disease are at the crossroads of hot subsectors of our Healthcare IT and Diagnostics franchises."

Arkstone's flagship OneChoice Report leverages human-in-the-loop ML and AI to generate optimal infectious disease treatment recommendations by analyzing laboratory results alongside patient data, and delivers patient-specific guidance to clinicians at the moment lab results are received. Already in use by laboratories across the United States and internationally, Arkstone is transforming how healthcare providers diagnose, treat, and understand infectious diseases.

"ARCHIMED's acquisition of Arkstone supercharges our mission and opens new horizons for innovation and global reach," said Ari Frenkel, MD, MPH, Chief Science Officer and Co-Founder of Arkstone. "This partnership ensures we have the resources, network, and strategic guidance to deliver our vision globally. Together, we'll expand access to the tools clinicians need to combat antimicrobial resistance and prescribe responsibly."

Following the acquisition, Arkstone will continue to operate with its existing team. The company's next phase will focus on rapid growth, further product development, and entry into new markets.

Dave Gross, Chief Technology Officer and Co-Founder of Arkstone, commented, "This partnership marks a transformative milestone for Arkstone. ARCHIMED's deep expertise and global presence will significantly enhance our ability to innovate rapidly and bring life-saving antimicrobial stewardship solutions to a broader global audience. We're thrilled to begin this exciting new chapter."

The partnership underscores the critical importance of antimicrobial stewardship and positions Arkstone as a global leader at the intersection of AI, infectious disease, and clinical decision support.

"This acquisition is a powerful affirmation of the deep trust we've earned with our partners and the world-class support our team delivers," said Sol Levi, Chief Customer Officer and Co-Founder at Arkstone. "This is an opportunity to bring our personalized approach to even more partners, innovate faster, and deepen the collaborative relationships that have always defined Arkstone's success."

As Arkstone enters this new chapter, it remains steadfast in its mission to empower clinicians, protect patients, and lead the future of precision-guided infectious disease clinical decision support.

About Arkstone Medical Solutions

Arkstone is a biotechnology company providing clinical decision support powered by ML and AI, helping healthcare providers optimize antimicrobial use. Arkstone's OneChoice Report empowers clinicians to prescribe with precision and confidence, fighting antimicrobial resistance and democratizing infectious disease expertise.

Media Contact: Sol Levi | 1-833-933-ARK(275)-3 | [email protected] | www.arkstone.ai

SOURCE Arkstone